| Literature DB >> 34296013 |
Abstract
The Brønsted acid-base neutralization was executed for synthesis of the anilinium carboxylate ionic liquids (ACILs), and obtained highly viscous liquids with yields about (90-94)%. These ILs were purified by distillation process and used vacuum oven, as well as characterized by FT-IR, UV spectroscopy and 1H-NMR. To evaluate the antimicrobial activity, the well diffusion method was used against eight human pathogenic bacteria, showing inhibition of zone at 13 mm-27 mm, and three fungi with result about 60%. Plus, the DFT functional from material studio 8.0 was used for evaluation of computational screening for estimating the chemical reactivity, HOMO, LUMO and HOMO-LUMO gap, recorded from -7.252 to -8.20 kcal/mol. The IL05 has showed about -6.5 kcal/mol docking score as standard inhibitor, as and higher than starting. Form AMDET properties, it has revealed that they have low toxicity, higher absorption through the biological system and non-carcinogenic. Finally, the electronegative groups, such as F, Cl and Br atoms in anion can show the higher antimicrobial activity and molecular docking score among all others while F atom containing IL05 shows the highest docking score and antimicrobial activity. However, it is concluded that rather than long large alkyl chain of anion, F atom (the highest electronegative atom) containing anion is better for biologically significance ILs.Entities:
Keywords: Antimicrobial activity; DFT; HOMO; Ionic liquids; LUMO and ADMET; Well-diffusion method
Year: 2021 PMID: 34296013 PMCID: PMC8282962 DOI: 10.1016/j.heliyon.2021.e07509
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Synthesis reaction scheme.
Zone of inhibition against bacteria in mm scale without 8 mm hole of well for 1000 mM.
| IL01 | IL02 | IL03 | IL04 | IL05 | Control | Starting | |
|---|---|---|---|---|---|---|---|
| 18 | 20 | 21 | 18 | 24 | 0 | 0 | |
| 16 | 17 | 19 | 14 | 25 | 0 | 0 | |
| 16 | 19 | 21 | 20 | 23 | 0 | 0 | |
| 17 | 14 | 20 | 20 | 24 | 0 | 0 | |
| 16 | 14 | 21 | 18 | 19 | 0 | 0 | |
| 14 | 16 | 15 | 27 | 27 | 0 | 0 | |
| 13 | 14 | 17 | 13 | 19 | 0 | 0 | |
| 16 | 14 | 17 | 17 | 20 | 0 | 0 |
Zone of inhibition of antifungal activity.
| Chemicals tested | Zone of growth (in mm) | %, growth percentage | ||||
|---|---|---|---|---|---|---|
| Control | 28 mm | 41mm | 38 mm | 100 % | 100% | 100 % |
| Staring material | 28 mm | 41mm | 38 mm | 100 % | 100 % | 100 % |
| IL01 | 15 | 19 | 17 | 53.00 % | 46.34% | 44.70% |
| IL02 | 14 | 17 | 16 | 50.00 % | 41.46% | 42.10% |
| IL03 | 13 | 17 | 15 | 46.43 % | 41.46% | 36.58% |
| IL04 | 11 | 16 | 13 | 39.28% | 39.02% | 34.21% |
| IL05 | 12 | 15 | 13 | 42.85% | 36.58% | 34.21% |
MIC.
| 1000 mM | 750 mM | 500 mM | 250 mM | 125 mM | MIC | |
|---|---|---|---|---|---|---|
| IL01 | 18 | 11 | 6 | 0 | 0 | 250 |
| IL02 | 20 | 16 | 9 | 0 | 0 | 250 |
| IL03 | 21 | 14 | 7 | 0 | 0 | 250 |
| IL04 | 18 | 10 | 6 | 0 | 0 | 250 |
| IL05 | 24 | 16 | 11 | 7 | 0 | 125 |
| IL01 | 16 | 10 | 5 | 0 | 0 | 250 |
| IL02 | 14 | 7 | 0 | 0 | 0 | 500 |
| IL03 | 21 | 19 | 9 | 0 | 0 | 250 |
| IL04 | 18 | 11 | 6 | 0 | 0 | 250 |
| IL05 | 19 | 13 | 9 | 6 | 0 | 125 |
Figure 2The relative effect of anion on antibacterial activity.
Data for percentage of inhibition.
| Chemicals tested | Percentage of Inhibition | ||
|---|---|---|---|
| Control | 0% | 0% | 0 % |
| Staring material | 0% | 0% | 0% |
| IL01 | 47.00% | 53.66% | 55.30% |
| IL02 | 50.00% | 58.54% | 63.43% |
| IL03 | 53.58% | 58.54% | 55.30% |
| IL04 | 60.72% | 60.98% | 65.79% |
| IL05 | 57.15% | 63.42 % | 65.79% |
Figure 3Frontier orbital diagram of HOMO LUMO.
Figure 4a) Ligand in protein pocket b) 2D picture of ligand protein interaction c) Hydrogen bonding pose of ligand protein d) Hydrophobicity; of IL03 against Bacillus cereus (+).
HOMO, LUMO, HOMO–LUMO gap, Ionization potential (I) and Electron affinity.
| c | IL02 | IL03 | IL04 | IL05 | IL06 | IL07 | IL08 | |
|---|---|---|---|---|---|---|---|---|
| HOMO, eV | -8.582 | -7.332 | -8.434 | -8.443 | -9.485 | -8.453 | -9.351 | -7.450 |
| LUMO, eV | -0.601 | -1.594 | -0.732 | -0.736 | -1.181 | -0.910 | -1.151 | -1.947 |
| LUMO-HOMO gap, eV | 7.981 | 5.738 | 7.702 | 7.713 | 8.303 | 7.543 | 8.200 | 5.503 |
| Ionization potential(I), eV | 8.582 | 7.332 | 8.434 | 8.443 | 9.485 | 8.453 | 9.351 | 7.450 |
| Electron affinity (A), eV | 0.601 | 1.594 | 0.732 | 0.736 | 1.181 | 0.910 | 1.151 | 1.947 |
| Chemical potential (μ), eV | 4.591 | 4.463 | 4.583 | 4.589 | 5.333 | 4.681 | 5.251 | 4.698 |
| Electrophilicity index(ω), eV | 2.641 | 3.471 | 2.727 | 2.734 | 3.425 | 2.905 | 3.362 | 4.011 |
| Electronegativity ), eV | -4.591 | -4.463 | -4.583 | -4.589 | -5.333 | -4.681 | -5.251 | -4.698 |
| Hardness (η), eV | 3.990 | 2.869 | 3.851 | 3.853 | 4.152 | 3.771 | 4.100 | 2.751 |
| Softness (σ), eV | 0.250 | 0.348 | 0.259 | 0.259 | 0.240 | 0.265 | 0.244 | 0.364 |
Docking score by interaction between ligand and macromolecule.
| Binding affinity (kcal/mol) | No of H bond | Total bonds | Binding affinity (kcal/mol) | No of H bond | Total bonds | Binding affinity (kcal/mol) | No of H bond | Total bonds | |
|---|---|---|---|---|---|---|---|---|---|
| IL01 | -5.9 | 04 | 05 | -5.8 | 03 | 04 | -5.4 | 03 | 05 |
| IL 02 | -6.6 | 02 | 04 | -6.1 | 02 | 07 | -5.8 | 01 | 05 |
| IL 03 | -6.0 | 02 | 04 | -5.8 | 02 | 07 | -6.0 | 04 | 05 |
| IL 04 | -5.8 | 03 | 08 | -5.5 | 02 | 06 | -6.0 | 03 | 04 |
| IL 05 | -6.7 | 03 | 06 | -6.0 | 03 | 08 | -6.5 | 02 | 06 |
| IL06 | -5.5 | 00 | 03 | -5.9 | 01 | 03 | -6.2 | 02 | 04 |
| IL 07 | -6.2 | 04 | 05 | -6.0 | 03 | 06 | -6.3 | 03 | 04 |
| IL08 | -6.0 | 02 | 04 | -5.8 | 00 | 04 | -6.4 | 03 | 05 |
| Starting | -2.8 | 00 | 03 | -3.0 | 00 | 03 | -2.8 | 00 | 04 |
Docking score by interaction between ligand and macromolecule.
| Compounds | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Amino acid residue | Bond distance | Bond type | Amino acid residue | Bond distance | Bond type | Amino acid residue | Bond distance | Bond type | |
| IL01 | LYS = 110 | 4.15 | Pi alkyl | SER-21 | 3.01 | H bond | ASN-63 | 2.6 | H bond |
| SER-388 | 2.45 | H bond | GLY-385 | 2.80 | H bond | ASN-20 | 2.73 | H bond | |
| LUE-387 | 2.35 | H bond | GLU-382 | 2.43 | H bond | GLN-200 | 2.10 | H bond | |
| ASN-386 | 3.60 | H bond | ALA-18 | 3.81 | Pi sigma | ASP-99 | 5.48 | Attractive charge | |
| ASN-386 | 5.15 | C– H bond | TRP-22 | 6.82 | Pi-pi stacked | ||||
| IL 02 | LEU-387 | 2.52 | H bond | ARG-386 | 2.04 | H bond | ASN-20 | 2.74 | H bond |
| SER-388 | 2.59 | H bond | SER-14 | 3.21 | H bond | ASN-63 | 2.56 | H bond | |
| LYS-110 | 4.08 | Pi alkyl | MET-30 | 5.42 | Pi alkyl | GLN-200 | 2.13 | H bond | |
| LEU-387 | 5019 | Pi alkyl | VAL-15 | 5.12 | Pi alkyl | GLN-200 | 2.18 | H bond | |
| LEU-197 | 4.96 | Pi alkyl | TRP-22 | 6.84 | Pi alkyl | ||||
| GLU-483 | 2.48 | Attractive charge | |||||||
| GLU-483 | 3.04 | Salt bridge | |||||||
| IL 03 | SER-383 | 2.19 | H bond | ARG-386 | 2.06 | H bond | ASN-63 | 2.76 | H bond |
| SER-385 | 2.91 | H bond | SER-14 | 3.10 | H bond | GLN-300 | 2.56 | H bond | |
| ASP-336 | 3.48 | Pi anion | GLU-483 | 2.92 | Attractive charge | ASN-20 | 2.11 | H bond | |
| ASP-336 | 4.42 | Attractive charge | GLU-483 | 2.44 | Salt bridge | GLN-300 | 2.22 | H bond | |
| LYS-103 | 4.06 | Pi alkyl | VAL-15 | 5.12 | Pi alkyl | REP-22 | 6.84 | Pi alkyl | |
| HIS-201 | 4.85 | Pi alkyl | LEU-197 | 5.00 | Pi alkyl | ||||
| MET-30 | 3.85 | Pi alkyl | |||||||
| IL 04 | SER-385 | 2.81 | H bond | SER-14 | 2.67 | H bond | ASN-63 | 2.57 | H bond |
| SER-383 | 1.96 | H bond | SER-14 | 2.43 | H bond | GLN-200 | 2.11 | H bond | |
| ASP-336 | 3.48 | Pi anion | GLU-483 | 1.17 | Salt Bridge | GLN-200 | 2.23 | H bond | |
| ASP336 | 4.63 | Attractive charge | MET-30 | 4.94 | Pi alkyl | TRP-22 | 6.83 | Pi-pi stacked | |
| LYS-103 | 5.02 | Pi alkyl | MET-30 | 4.82 | Pi alkyl | ||||
| HIS-201 | 5.09 | Pi alkyl | LEU-197 | 4.11 | Pi alkyl | ||||
| LYS-143 | 4.25 | Pi alkyl | |||||||
| SER-142 | 3.16 | C–H bond | |||||||
| IL 05 | PHE-135 | 2.08 | H bond | SER-14 | 3.31 | H bond | ASN-20 | 2.75 | H bond |
| PHE-135 | 2.22 | H bond | ARG-386 | 2.06,2.86 | H bond | ASN-20 | 2.18 | H bond | |
| ASP-173 | 2.94 | H bond | GLU-483 | 2.55,2.85 | Salt Bridge | GLN-200 | 3.02 | Halogen bond | |
| GLU-134 | 3.68 | Halogen bond | LEU-197 | 4.97 | Pi alkyl | SER-111 | 3.29 | Halogen bond | |
| GLU-134 | 3.46 | Halogen bond | MET-30 | 5.39 | Pi alkyl | ASP-99 | 3.41 | Halogen bond | |
| ASP-173 | 4.75 | Attractive charge | VAL-15 | 5.23 | Pi alkyl | ASP-99 | 2.97 | Halogen bond | |
| IL06 | ASP-293 | 3.17 | Salt Bridge | SER-14 | 2.59,2.35 | H bond | GLN-200 | 2.23,2.14 | H bond |
| TYR-267 | 4.19 | Pi alkyl | GLU-483 | 2.21,2.41 | Salt Bridge | ASN-63 | 2.56 | H bond | |
| LEU-292 | 5.41 | Pi alkyl | MET-30 | 5.68 | Pi anion | TRP-22 | 6.92 | Pi-pi stacked | |
| TYR-07 | 4.78 | Pi alkyl | |||||||
| IL 07 | PHE-276 | 2.09 | H bond | SER-14 | 2.64,2.58 | H bond | ASN-20 | 2.89 | H bond |
| PHE-276 | 2.14 | H bond | ARG-386 | 2.43 | H bond | ASN-63 | 2.07 | H bond | |
| ASP-372 | 2.70 | H bond | GLU-483 | 4.49 | Attractive charge | GLN-200 | 2.17 | H bond | |
| ASP-372 | 2.62 | H bond | VAL-15 | 5.13 | Pi alkyl | TRP-22 | 6.51 | Pi-pi stacked | |
| ASN-275 | 5.27 | Pi-pi stacked | LEU-197 | 4.60 | Pi alkyl | ||||
| IL08 | GLN-348 | 2.11 | H bond | GLU-483 | 2.40 | Salt Bridge | GLN-128 | 2.30,2.09 | H bond |
| GLN-348 | 2.37 | H bond | ARG-386 | 3.51 | Salt Bridge | GLY-56 | 3.68 | C–H bond | |
| ALA-325 | 5.22 | C–H bond | MET-30 | 5.70 | Pi anion | PHE-206 | 4.91 | Pi-pi stacked | |
| GLN-326 | 4.89 | Pi alkyl | ALA-18 | 4.62 | Pi alkyl | ILE-130 | 5.37 | Pi alkyl | |
Data of Physiochemical properties and Lipinski rule.
| MW | NRB | HBA | HBD | TPSA | Lipophilicity Log Po/w | Log Kp (skin, permeation) cm/s | Lipinski rule | GI absorption | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Score | violation | |||||||||
| IL01 | 140.16 | 0 | 3 | 2 | 64.94 | 0.08 | -6.66 | Yes | 0 | High |
| IL 02 | 154.19 | 0 | 3 | 2 | 40.54 | 0.06 | -6.75 | Yes | 0 | High |
| IL 03 | 168.21 | 2 | 3 | 2 | 40.54 | 0.40 | -6.50 | Yes | 0 | High |
| IL 04 | 182.24 | 2 | 3 | 2 | 40.54 | 0.74 | -6.33 | Yes | 0 | High |
| IL 05 | 208.16 | 1 | 6 | 2 | 64.94 | 0.88 | -6.28 | Yes | 0 | High |
| IL06 | 196.27 | 3 | 3 | 2 | 40.54 | 1.10 | -5.63 | Yes | 0 | High |
| IL 07 | 257.52 | 1 | 3 | 2 | 40.54 | 0.91 | -6.07 | Yes | 0 | High |
| IL08 | 390.87 | 1 | 3 | 2 | 40.54 | 1.21 | -6.52 | Yes | 0 | High |
Note: MW: molecular weight, HBD: No. of H-bond donors, HBA: No. of H-bond acceptor, NRB; No. of rotatable bonds, TPSA: topological polar surface area.
Pharmacokinetic parameters of photochemicals.
| Drug Candidate | Human Intestinal Absorption (+ve/-ve) | Human oral bioavailability (+ve/-ve) | Blood Brain Barrier (+ve/-ve) | P-glycoprotein substrate/inhibitor | Subcellular localization | CYP substrate | CYP Inhibitor | Carcinogenicity (binary) | Fish aquatic toxicity (+ve/-ve) | Water solubility | Acute Oral Toxicity (kg/mol) | Tetrahymena pyriformispIGC50 (ug/L) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL01 | + | - | + | −/− | Mitochondria | - | - | - | 0.746 | -1.138 | 2.657 | 0.284 |
| IL 02 | + | - | + | −/− | Mitochondria | - | - | - | 2.782 | -1.854 | 1.842 | -0.266 |
| IL 03 | + | - | + | −/− | Mitochondria | - | - | - | 2.510 | -1.847 | 1.972 | 0.171 |
| IL 04 | + | - | + | −/− | Mitochondria | - | - | - | 2.121 | -2.038 | 2.217 | 0.273 |
| IL 05 | + | - | + | −/− | Mitochondria | - | - | - | 1.632 | -2.200 | 2.545 | -0.071 |
| IL06 | + | - | + | −/− | Mitochondria | - | - | - | 1.894 | -2.490 | 2.044 | 0.315 |
| IL 07 | + | - | + | −/− | Mitochondria | - | - | - | 1.473 | -2.882 | 2.215 | 0.192 |
| IL08 | + | - | + | −/− | Mitochondria | - | - | - | 1.681 | -2.928 | 2.224 | 0.436 |